Alzheimer's Archives

News and Trends 17 Jul 2015

AC Immune receives Milestone Payment for Alzheimer Antibody

AC Immune received a first milestone payment from Roche’s subsidiary Genentech. The latter picked up a potential Alzheimer’s drug worth developing towards clinical trials. The collaboration began in 2012 with Genentech’s promising milestone payments amounting to more than €384M (CHF400M). Alzheimer’s disease will be one of the biggest burdens of tomorrow’s society showing a dramaticaly […]

July 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Jul 2015

Probiodrug bets on basic research with Harvard’s collaboration

Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School. Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s disease. […]

July 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jul 2015

First-in-human successful Phase I for an Alzheimer’s vaccine

AXON Neuroscience has completed a pioneer Phase I that offers new hope for millions of patients with Alzheimer’s disease. This makes AXON the first company to successfully complete this clinical trial for a vaccine that targets diseased tau proteins, which cause neural degeneration. Alzheimer’s disease is characterized by the presence of prejudicial forms of protein […]

July 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jul 2015

Biogen is back home with its $1Bn Swiss production plant

Biogen is coming back home. The American company is opening a production plant in Switzerland that will employ 400 professionals. To this aim, the company will invest €0.9Bn ($1Bn) into the project. Biogen was founded back in 1978 in Geneva, Switzerland, and now aims at expanding its manufacturing network by opening a biopharmaceutical plant in […]

July 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Jul 2015

Roche and Evotec knocked down by their Alzheimer candidate

The progressive aging of the population in developed countries is turning Alzheimer into one of the biggest medical challenges of our times. And it looks like it is going to remain an unresolved problem for the moment, as Roche’s candidate failed its last clinical trial. The drug, developed in collaboration with German Evotec, didn’t meet […]

July 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 May 2015

Axovant banks on GSK’s scrapped project

Last December, Axovant acquired for €4.5M ($5 million) the drug candidate SB742457 from GlaxoSmithKline. Four months later, the company announced its initial public offering to raise up to €154M ($173 million). Why is this newly funded company betting on the leftovers of the Big Pharma? The drug candidate SB742457 is a selective 5-HT6 receptor antagonist, developed as an oral […]

May 13, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 26 Mar 2015

The Genomic Portrait of Iceland

A package of four landmark papers were published yesterday in the online edition of Nature Genetics. The research, written by a team of deCODE scientists, was built on whole-genome sequence data from more than 100,000 people from across Iceland. The four milestone studies together present the most detailed portrait of a population yet assembled using the latest technology […]

March 26, 2015 - 4 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS) diseases. Alkermes has successfully completed preclinical development and expects to initiate the first clinical study of its newest candidate, ALKS 7119, in the third quarter of 2015. ALKS 7119 has a multivalent mechanism of action […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Aug 2014

Stemedica International succeed in a pre-clinical trial to treat Alzheimer’s disease with stem cells

Stemedica International, a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. The results demonstrated a greater than 30% decrease in amyloid beta (Abeta) plaques in […]

August 21, 2014 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us